Assistant Research

Karine A. COHEN-SOLAL

Tel: 732-***-****

E-mail: ********@*******.***

PROFESSIONAL SUMMARY

Highly skilled Assistant Professor with over 17 years in Cancer Research, defining new targets for cancer therapy and understanding drug resistance.

Developed interest and expertise in understanding how targeted therapy and immunotherapy trigger remodeling of the tumor microenvironment resulting in acquired resistance and therapeutic failure.

Research leader with a 10-year expertise in leading an academic research laboratory and establishing teams of scientific collaborations from interdisciplinary areas, including basic and translational cancer research, cancer immunology and bioinformatics.

Harnessed Bioinformatic tools to address the clinical relevance of in vitro and preclinical studies.

Experienced in writing protocols for IRB, in close collaboration with clinicians directly involved in clinical trials as principal investigators of NIH/R01/R21 grants.

Highly experienced writer for over 26 years, published in high-impact scientific journals. Successful recipient of awards and research scholar grants.

Delivered oral presentations at international scientific meetings in the oncology field.

Familiar with Microsoft Word, Microsoft PowerPoint, Microsoft Excel, Endnote, Adobe Professional, and Adobe Photoshop

Familiar with AMA style

PROFESSIONAL EXPERIENCE

Member, Rutgers Cancer Institute of New Jersey, 04/2008 – 06/2017

Assistant Professor of Medicine, 08/2006 – 06/2017

Worked as a Principal Investigator for over 10 years in charge of an academic research laboratory conducting basic and translational research.

Identified new targets for melanoma therapy and developed new approaches for understanding resistance to tumor suppression mechanisms in cancer. One of my accomplishments was the demonstration that constitutive activation of the MAPK pathway in advancer cancer feeds directly into the Transforming Growth factor beta (TGFβ) signaling pathway to promote TGFβ-driven pro metastatic activity at the expense of TGFβ tumor suppressive activity.

Forged collaborations with Medical Doctors, in charge of translational research and clinical trials. One of my accomplishments was to show that the administration of the promising agent riluzole, a glutamate release inhibitor, to melanoma patients was triggering feedback mechanisms and activating the TGFβ and WNT pathways, major players in distant melanoma metastasis, thereby compromising riluzole’s anti-tumor properties.

Forged collaborations with cancer immunologists involved in Melanoma and Breast Cancer research. These ongoing collaborations aim to understand how pro-metastatic cancer cells repurpose the expression of their receptors to inhibit the anti-tumor immune response.

Developed new concepts for understanding resistance to targeted therapy through immunosuppression. One of our accomplishments resides in approaching the resistance to targeted therapy through up regulated expression of the immune checkpoint PD-L1 at the membrane of cancer cells.

Identify pro-oncogenic transcription factors as a means to delineate more druggable downstream targets

One accomplishment is the demonstration that the new melanoma target that we identified, the transcription factor RUNX2, regulates membrane receptors involved in resistance to BRAF V600E targeted therapy, which are druggable.

Interpreted research findings and summarized data into peer-reviewed articles, resulting in high-impact

publications in Oncology, such as Carcinogenesis, Cancer Letters, Oncotarget and Drugs Discovery Today.

Applied and received research scholar grants from American Foundations, such as the American Cancer Society and the New Jersey Commission on Cancer Research

Family Leave, 06/2004-07/2006

Research Associate/Junior Faculty, Rutgers University, Piscataway NJ 08854), 06/2002 - 02/2004

Developed new models of melanoma development and identified new targets for melanoma treatment. One major accomplishment was the identification of a member of G-protein-coupled receptors, the metabotropic glutamate receptor 1 (GRM1) as a new target for therapeutic intervention. This work was the basis for the clinical trial involving the aforementioned glutamate release inhibitor riluzole. A genetically engineered mouse model overexpressing GRM1 is still being used until today as a melanoma model and in preclinical studies to inform the design of future clinical trials not only for melanoma but also for other cancer types such as Breast Cancer.

Postdoctoral training, at the Susan Lehman Cullman Laboratory for Cancer Research – Rutgers University, Piscataway, New Jersey, 06/1999-05/2002

Developed vivid interest in cancer research through the development of new melanoma models, including transgenic models of melanoma.

Introduced new techniques into the laboratory to address the challenges associated with identifying a new melanoma target.

Refined writing experience through program projects and proposals, abstracts for scientific meetings, manuscript submissions and establishment of new technical protocols.

Prepared oral presentations (Microsoft PowerPoint) and delivered communications at scientific meetings.

Postdoctoral training, at the Gustave Roussy Institute, Laboratory “Hématopoiesis and Stem Cells”, INSERM U362, Villejuif, France, 01/1995-04/1999

Delineate the regulation of the thrombopoietin, which regulates platelet production, and of its receptor MPL in mouse models

Developed independent writing, through abstracts, posters, manuscript submissions and fellowship

applications. Published in high impact scientific journals in Hematology such as Blood.

EDUCATION

1990-1994 Ph.D in Cellular and Molecular Biology, University of Paris VI, France

1988-1990 European Master in Biology/Biochemistry (Master of Science with more informatics and research training), Ecole Normale Supérieure, Paris, France

1988-1989 Master’s Degree in Cellular Biology, University of Paris VI, France

MENTORING AND TEACHING EXPERIENCE

1) Postdoctoral Mentoring:

-Dr. Khanh Dinh (October/2009-March/2010): Postdoctoral Associate. He is now Manager, Regulatory Affairs & Quality Assurance at Diagnostica Stago.

-Dr.Walid Abushahba (June 2010-March 2012): Postdoctoral Associate. He is now Assistant Professor at Montclair State University.

-Dr. Murugabaskar Balan (Feb.2011-September 2011): Postdoctoral Associate. He is now Instructor in Pediatrics, at Boston Children's Hospital, Harvard Medical School.

-Dr. Oyenike Olabisi (Dec. 2010- August 2012): Postdoctoral Associate. She is now Assistant Professor at the University of Delaware.

-Dr. Rajeev Boregowda (July 2012- June 2017): Research Associate III. He is now Research Scientist at BMS.

-Dr. Michael Bryan (Dec. 2015 – November 2016): Research Assistant

2) Other Mentoring activities:

-Johene Sindac, (Summer 2011- 4 hours per week during the school year -March 2012): High school student, from the CURE (Continuing Umbrella for Research Education) program. She is now a student at the School of Arts and Sciences at Rutgers University.

-Priyanka Lalitha Ram: Rotation student in the Graduate Program in Biomedical Sciences. She is now Research Associate II at Regeneron Pharmaceuticals.

-Tejasvi Gowda: Summer Internship Student. She is now a Medical Student at the University of Pittsburgh School of Medicine.

-Rahul Muchintala: High school student (not from the CURE program). He is currently finishing pre-medical studies.

-Prawallika Gangidi: Summer Internship Student. She is now Teaching Assistant at Cornell University College of Engineering.

3) Courses:

-Molecular Medicine Seminar Course

-Molecular Biosciences – Pharmacology Track – Cancer Biology track.

HONORS AND AWARDS

2014-2016 Elizabeth and Barets O. Benjamin Foundation Career Development Award for Women in Cancer Research. Title: Role of the transcription factor RUNX2 in promoting melanoma development and progression.

2009-2013 Research Scholar Grant in Basic, Preclinical, Clinical and Epidemiology Research from the American Cancer Society. Title: Transforming Growth Factor beta signaling and melanoma development 116683-RSG-09-087-01-TBE (ACS)

2009-2011 Grant from the New Jersey Commission on Cancer Research. Title: The glutamatergic pathways in melanoma (Multi-PI grant). 09-1143-CCR-EO (NJCCR)

200*-****-**** Research Development Award from the Cancer Institute of New Jersey. Title: Role of Transforming Growth Factor beta in melanoma

2006-2009 Re-entry into Biomedical and Behavioral Research Careers Award. Title: Growth control of normal and malignant keratinocytes. 3RO1CA041556-20S1

2004-2006 Grant from the Melanoma Research Foundation

2003-2004 Grant from the New Jersey Commission on Cancer Research

2002 Gallo Award (from The Cancer Institute of New Jersey and the New Jersey Commission on Cancer Research attributed to the best presentations and posters of the annual Cancer Retreat of New Jersey)

2000 Gallo Award

1999-2000 French Foundation "Fondation pour la Recherche Medicale", Postdoctoral Fellowship

1998-1999 "Fournier Pharmaceuticals", United Kingdom, Postdoctoral Fellowship

1997-1998 French Foundation "Ligue Nationale contre le Cancer", Postdoctoral Fellowship

1995-1997 "ZymoGenetics", Seattle, WA, Postdoctoral Fellowship

1993-1994 French Foundation "Association pour la Recherche contre le Cancer", Graduate Fellowship

1990-1993French Ministry of Research and Technology, Graduate Fellowship

GRANT HISTORY

E. and B. O. Benjamin Foundation K. Cohen-Solal (PI) 07/01/2014 – 06/30/2016

Career Development Award for Women in Cancer Research

Title: Role of the transcription factor RUNX2 in promoting melanoma development and progression.

The goals of the study are to investigate mechanisms of RUNX2 overexpression in melanoma by the TGF beta and the Wnt pathways, as well as amplification.

Role: PI

1RO1CA149627-01 J. Goydos (PI) 07/01/2010 - 06/30/2015

Combination therapy that targets glutamate signaling in melanoma

The goal of this study are to perform a phase I/II clinical trial of Riluzole and the multi-kinase inhibitor Sorafenib in patients with advanced stage melanoma and to investigate whether Riluzole effects are mediated in part by negative regulation of the PI3K/AKT pathway in melanoma.

Role: Co-investigator

116683-RSG-09-087-01-TBE (ACS) K. Cohen-Solal (PI) 01/01/09-12/31/2013

Transforming Growth Factor beta signaling and melanoma development

The goal of this study is to determine the role of the Smad linker phosphorylation in the resistance to TGFβ-mediated tumor suppressive activities in melanoma.

Role: PI

09-1143-CCR-EO (NJCCR) S. Chen (Lead PI, MPI) 06/26/2009 - 06/25/2011

The glutamatergic pathways in melanoma

The goals of this study are to perform preclinical studies of combination therapies, including the glutamate release inhibitor, Riluzole, and to analyze the signaling pathways affected by Riluzole.

Role: co-PI

3RO1CA041556-20S1 M.Reiss (PI) 05/01/2006 - 04/30/2010

Growth control of normal and malignant keratinocytes.

The goal of this study was to address the contribution of TGFβ signaling to the aggressive phenotype of melanoma.

Role: Recipient Reentry supplements to promote reentry into Biomedical and Behavioral Research

MANUSCRIPT REVIEWER, AWARD REVIEW AND MEMBERSHIP

- Reviewer: Journal reviewer for Carcinogenesis: 01/2011 – present

Reviewer for PLOS One, Oncotarget

Editorial Board Member: Drug Target Insights: 10/ 2012 - present

- RCINJ Breast Cancer Research Development Award Reviews

- RCINJ Impact Award Reviews

- Getting to Know Cancer Task Force (Member). Role: Assessing the Carcinogenic Potential of Low-Dose Exposures to Chemical Mixtures in the Environment: Focus on the Cancer Hallmark of Evading Growth Suppression: 2013-present:

- Member of the Society for Melanoma Research

PUBLICATIONS (From most recent)

1.Lasfar A., Zloza A., de la Torre A., Cohen-Solal K.A. IFN-λ: A New Inducer of Local Immunity against Cancer and Infections. Front Immunol (2016) 7:598. doi: 10.3389/fimmu.2016.00598. eCollection 2016.

2.Lasfar, A. de la Torre, A., Abushahba, W., Cohen-Solal, K.A., Castaneda, I., Yuan, Y., Reuhl, K., Zloza, A., Raveche, E., Laskin, D. L. and Kotenko S. V. Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth. Oncotarget (2016) 7, 492**-*****. doi 10.18632/oncotarget.10272.

3.Boregowda R.K., Medina D.J., Markert E., Bryan M.A., Chen W., Chen S., Rabkin A., Vido M.J., Gunderson S.I., Chekmareva M., Foran D.J., Lasfar A., Goydos J.S., Cohen-Solal K.A. The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma. Oncotarget (2016) 7, 296**-*****. doi 10.18632/oncotarget.8822.

4.Lasfar A, Zloza A and Cohen-Solal K.A. IFN-lambda therapy: current status and future perspectives. Drug Discov Today (2016) 21, 167-171.

5.Cohen-Solal, K.A., Boregowda, R.K. and Lasfar, A. RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression. Molecular Cancer (2015) 14, 137-147.

6.Goodson WH 3rd, Lowe L, Carpenter DO, Gilbertson M, Manaf Ali A, Lopez de Cerain Salsamendi A, Lasfar A, Carnero A, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, Olsen AK, Berg A, Barclay BJ, Zhou BP, Blanco-Aparicio C, Baglole CJ, Dong C, Mondello C, Hsu CW, Naus CC, Yedjou C, Curran CS, Laird DW, Koch DC, Carlin DJ, Felsher DW, Roy D, Brown DG, Ratovitski E, Ryan EP, Corsini E, Rojas E, Moon EY, Laconi E, Marongiu F, Al-Mulla F, Chiaradonna F, Darroudi F, Martin FL, Van Schooten FJ, Goldberg GS, Wagemaker G, Nangami G, Calaf GM, Williams G, Wolf GT, Koppen G, Brunborg G, Kim Lyerly H, Krishnan H, Ab Hamid H, Yasaei H, Sone H, Kondoh H, Salem HK, Hsu HY, Park HH, Koturbash I, Miousse IR, Scovassi AI, Klaunig JE, Vondráček J, Raju J, Roman J, Wise JP Sr, Whitfield JR, Woodrick J, Christopher JA, Ochieng J, Martinez-Leal JF, Weisz J, Kravchenko J, Sun J, Prudhomme KR, Narayanan KB, Cohen-Solal KA, Moorwood K, Gonzalez L, Soucek L, Jian L, D'Abronzo LS, Lin LT, Li L, Gulliver L, McCawley LJ, Memeo L, Vermeulen L, Leyns L, Zhang L, Valverde M, Khatami M, Romano MF, Chapellier M, Williams MA, Wade M, Manjili MH, Lleonart M, Xia M, Gonzalez MJ, Karamouzis MV, Kirsch-Volders M, Vaccari M, Kuemmerle NB, Singh N, Cruickshanks N, Kleinstreuer N, van Larebeke N, Ahmed N, Ogunkua O, Krishnakumar PK, Vadgama P, Marignani PA, Ghosh PM, Ostrosky-Wegman P, Thompson P, Dent P, Heneberg P, Darbre P, Sing Leung P, Nangia-Makker P, Cheng QS, Robey RB, Al-Temaimi R, Roy R, Andrade-Vieira R, Sinha RK, Mehta R, Vento R, Di Fiore R, Ponce-Cusi R, Dornetshuber-Fleiss R, Nahta R, Castellino RC, Palorini R, Abd Hamid R, Langie SA, Eltom S, Brooks SA, Ryeom S, Wise SS, Bay SN, Harris SA, Papagerakis S, Romano S, Pavanello S, Eriksson S, Forte S, Casey SC, Luanpitpong S, Lee TJ, Otsuki T, Chen T, Massfelder T, Sanderson T, Guarnieri T, Hultman T, Dormoy V, Odero-Marah V, Sabbisetti V, Maguer-Satta V, Rathmell WK, Engström W, Decker WK, Bisson WH, Rojanasakul Y, Luqmani Y, Chen Z, Hu Z. Carcinogenesis (2015) 36, Supplement 1, S254-S296.

7.Nahta, R., Al-Mulla, F., Al-Temaimi, R., Amedei, A., Andrade-Vieira, R., Bay, S., Brown, D., Calaf, G. M., Castellino, R.C., Cohen-Solal, K.A., Colacci, A., Cruickshanks,, N., Dent,, P., Di Fiore,, R., Forte, S., Goldberg, G. S., Hamid, R.A., Krishnan, H., Laird,, D. W., Lasfar, A., Marignani, P. A., Memeo, L., Mondello, C., Naus, C. C., Ponce-Cusi, R., Raju, J., Roy, D., Roy, R., Ryan, E., Salem, H. K., Scovassi, I., Singh, N., Vaccari, M., Vento, R., Vondracek, J., Wade, M., Woodrick, J. and Bisson, W. H. The Halifax Project: Assessing the Carcinogenic Potential of Low-Dose Exposures to Chemical Mixtures in the Environment: Focus on the Cancer Hallmark of Evading Growth Suppression. Carcinogenesis (2015) 36, Supplement 1, S2-S18.

8.Boregowda, R.K., Olabisi, O. O., Abushahba, W., Jeong, B.S., Haenssen, K. K., Chen, W., Chekmareva, M., Foran, D. J., Goydos, J. S. and Cohen-Solal, K. A. RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion. Cancer Letters (2014) 348, 61-70.

9.Lasfar A., Cook, J. R., Cohen-Solal, K. A., Reuhl, K., Kotenko, S. V., Langer, J. and Laskin, D. L. Critical role of the endogenous IFN ligand-receptors in type I and type II IFNs response. Immunology (2014) 142, 442-452.

10.Wen Y., Li J., Koo J., Shin S-S., Lin Y, Jeong B-S., Mehnert J.M., Chen S., Cohen-Solal K.A., and Goydos J.S. Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression. Cancer Research (2014) 74, 2499-2509.

11.Abushahba, W.*, Olabisi, O. O., *, Jeong, B-S., Boregowda, R. K., Wen, Y., Liu, F., Goydos, J. S., Lasfar, A. and Cohen-Solal, K. Non-canonical Smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanoma. *Equal contribution. PLoS One. 2012;7(10):e47312. doi: 10.1371/journal.pone.0047312.

12.Lasfar, A, Abushahba, W., Balan, M. and Cohen-Solal, K. Interferon lambda: A new sword in cancer immunotherapy. (2011) Clinical and Developmental Immunology (2011) 2011:349575.

13.Cohen-Solal, K., Merrigan, K., Chan, J. L.-K., Goydos J. S., Chen, W., Foran, D.J., Liu, F., Lasfar, A. and Reiss, M. Constitutive Smad linker phosphorylation in melanoma: A mechanism of resistance to Transforming Growth Factor-β-mediated tumor suppression. Pigment Cell Melanoma Res. (2011) 24, 512-524.

14.Lasfar, A. and Cohen-Solal, K. Resistance to Transforming Growth Factor-β-mediated tumor suppression in melanoma: Are multiple mechanisms in place? Carcinogenesis (2010) 31, 1710-1717.

15.Le, M. N., Chan, J. L.-K., Rosenberg, S., Nabatian, A., Merrigan, K., Cohen-Solal, K. and Goydos J. S. The glutamate release inhibitor Riluzole decreases migration, invasion and proliferation of melanoma cells. Journal of Investigative Dermatology (2010) 130, 2240-2249.

16.Marin, Y., Namkoong, J., Cohen-Solal, K., Shin, S., Martino, J., Oka, M. and Chen, S. Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCe. Cell Signaling (2006) 18, 1279-1286.

17.Cohen-Solal, K., Sood, R., Marin, Y., Crespo-Carbone, S.M., Sinsimer, D., Martino, J.J., Robbins, C., Makalowska, I., Trent, J.M. and Chen, S. Identification and characterization of mouse Rab 32 by mRNA and protein expression analysis. Biochimica Biophysica Acta (2003) 1651, 68-75.

18.Pollock, P.*, Cohen-Solal, K.*, Sood, R.*, Namkoong, J., Koganti, A., Zhu, H., Robbins, C., Makalowska, I., Martino, J.M., Shin, S., Marin, Y., Roberts, K. G., Yudt, L.M., Chen, A., Cheng, J., Incao, A., Pinkett, H.W., Graham, C.L., Dunn, K., Galdzicki, M., Crespo-Carbone, S.M., Mackason, K. R., Ryan, K.B., Sinsimer, D., Goydos, J., Reuhl, K. R., Eckhaus, M., Meltzer, P.S., Pavan, W.J., Trent, J.M. and Chen, S. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nature Genetics (2003) 34, 108-112. * Equal contribution

19.Cohen-Solal, K., Crespo-Carbone, S.M., Namkoong, J., Mackason, K. R., Roberts, K. G, Reuhl, K. R. And Chen, S. Progressive appearance of pigmentation in amelanotic melanoma lesions. Pigment Cell Research (2002) 15, 282-289.

20.Mitjavila-Garcia, M.T., Cailleret, M., Godin, I., Nogueira, M.M., Cohen-Solal, K., Schiavon, V., Lecluse, Y., Le Pesteur, F., Lagrue, A.H. and Vainchenker, W. Expression of CD41 on hematopoietic progenitors derived from embryonic cells. Development (2002) 129, 2003-2013.

21.Cohen-Solal, K., Reuhl, K. R., Ryan, K. B., Roberts, K. G. and Chen, S. Development of cutaneous amelanotic melanoma in the absence of a functional tyrosinase. Pigment Cell Research (2001) 14, 466-474.

22.Cohen-Solal, K., Vitrat, N., Titeux, M., Vainchenker, W. and Wendling, F. High-level expression of Mpl in platelets and megakaryocytes is independent of thrombopoietin. Blood (1999) 93, 2859-2866.

23.Riviere, C., Subra, F., Cohen-Solal, K., Cordette-Lagarde, V., Letestu, R., Auclair, C., Vainchenker, W. and Louache, F. Phenotypical and a functional evidence for the expression of CXCR4 receptor during megakaryocytopoiesis. Blood (1999) 93, 1511-1523.

24.Wendling, F., Cohen-Solal, K., Villeval, J. L., Debili, N. and Vainchenker, W. Mpl ligand or Thrombopoietin: Biological activities. Biotherapy (1998) 10, 269-277.

25.Goncalves, F., Lacout, C., Feger, F., Cohen-Solal, K., Guichard, J., Cramer, E., Vainchenker, W. and Dumenil, D. Inhibition of erythroid differentiation and induction of megakaryocytic (MK) differentiation by thrombopoietin (TPO) are regulated by two different mechanisms in TPO dependent UT-7/c-mpl and TF-1/c-mpl cell lines. Leukemia (1998) 12, 1355-1366.

26.Taksin, A. L., Cohen-Solal, K., Le Couedic, J.P., Abina, M. A., Villeval, J. L., Debili, N., Casadevall, N., Vainchenker, W. and Wendling, F. Myelofibrosis: Experimental models and human studies. Stem Cells (1998) 16, 155-164.

27.Vitrat, N., Cohen-Solal, K., Norol, F., Cramer, E., Vainchenker, W., Wendling, F. and Debili, N. Compared effects of Mpl ligand and other cytokines on human MK differentiation. Stem Cells (1998) 16, 37-51.

28.Vitrat, N., Cohen-Solal, K., Pique, C., Le Couedic, J.P., Norol, F., Larsen, A.K., Katz, A., Vainchenker, W. and Debili, N. Endomitosis of human megakaryocytes are due to abortive mitosis. Blood (1998) 91, 3711-3723

29.Mitjavila, M. T., Filippi, M. D., Cohen-Solal, K., Le Pesteur, F., Vainchenker, W. and Sainteny, F. The Mpl-ligand is involved in the growth-promoting activity of the murine stromal cell line MS-5 on ES cell-derived hematopoiesis. Exp. Hematol. (1998) 26, 124-134.

30.Villeval, J. L., Cohen-Solal, K., Tulliez, M., Giraudier, S., Guichard, J., Burstein, S., Cramer, E., Vainchenker, W. and Wendling, F. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood (1997) 90, 4369-4383.

31.Cohen-Solal, K., Debili, N., Vainchenker, W. and Wendling, F. Thrombopoietin (Mpl ligand) and the regulation of platelet production. Eur. Cytokine Netw. (1997) 8, 311-314.

32.Abina, M. A., Villeval, J.L., Cohen-Solal, K., Vainchenker, W. and Wendling, F. Myélofibrose par excès de thrombopoiétine. Médecines/Sciences (1997) 13, 1053-1057.

33.Cohen-Solal, K., Debili, N., Vainchenker, W. and Wendling, F. Thrombopoietin (Mpl ligand) and the regulation of platelet production. Thrombosis and Haemostasis (1997) 78, 37-41.

34.Cohen-Solal, K., Villeval, J. L., Titeux, M., Lok, S., Vainchenker, W. and Wendling, F. Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis. Blood (1996) 88, 2578-2584.

35.Cohen-Solal, K., Debili, N., Villeval, J. L., Vainchenker, W. and Wendling, F. Mpl-Ligand and the regulation of megakaryocytopoiesis. Hämostaseologie (1996) 16, 97-106.

36.Perrot-Applanat, M., Cohen-Solal, K., Milgrom, E. and Finet, M. "Progesterone receptor expression in human saphenous vein". Circulation (1995) 92, 2975-2983.

37.Chauchereau, A., Cohen-Solal, K., Jolivet, A., Bailly, A. and Milgrom, E. "Phosphorylation sites in ligand-induced and ligand-independent activation of the progesterone receptor". Biochemistry (1994) 33, 143**-*****.

38.Cohen-Solal, K., Bailly, A., Rauch, C., Quesne, M. and Milgrom, E. "Specific binding of progesterone receptor to progesterone-responsive elements does not require prior dimerization". Eur. J. Biochem. (1993) 214, 189-195.

All articles available at my NCBI:

https://www.ncbi.nlm.nih.gov/sites/myncbi/1lM4qlPjWv1k3/bibliography/45764526/public/?sort=date&direction=ascending

Submitted article

Cohen-Solal K.A., Kaufman H.L. and Lasfar A. Transcription Factors as Critical Players in Melanoma Invasiveness, Drug Resistance and Opportunities for Therapeutic Drug Development. In revision in Pigment Cell and Melanoma Research.

Book Chapter:

Lasfar, A. and Cohen-Solal, KA. (2011) Emergence of IFN-lambda as a potential antitumor agent. In Targets in Gene Therapy. Edited by Yongping You, InTech Open Access Publisher.

REFERENCES

Available upon request

Contact this candidate